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Introduction: 123I-ioﬂupane SPECT is a powerful method to assess nigrostriatal dopamine system 
integrity. Several independent studies have shown that 1e15% of patients with suspected degenerative 
parkinsonism, mainly PD, have scans without evidence of dopaminergic deﬁcit (SWEDD). It has been 
proposed that most SWEDD patients either present with a non-degenerative condition mimicking PD, 
such as atypical tremor or dystonia, or demonstrate an abnormal scan when repeated later. We here 
hypothesized that scan interpretation methods may also play a crucial yet underestimated role in this 
issue.
Methods: We previously established age-dependent reference values of striatal uptake by analyzing 
scans from a cohort of patients with non-degenerative conditions. We then studied a large population 
with well-established degenerative parkinsonism (N ¼ 410, 80% with PD), using identical imaging pro-
tocol, to evaluate the prevalence of patients with normal scans based on routine visual assessment. Each 
scan was eventually reassessed using the same automated method as for controls and a detailed 3D 
analysis.
Results: Ten potential SWEDD cases (2.4%) were identiﬁed. However, both reassessment methods 
independently showed that these scans were all outside reference limits and/or visually abnormal when 
reexamined carefully, except for one case (0.2%) with corticobasal syndrome.
Conclusion: SPECT misinterpretation emerges as an important contributor to the SWEDD population, 
suggesting that suspected SWEDD cases should prompt not only a serious diagnosis challenge but, 
equally important, a detailed scan reassessment. True SWEDD cases seem extremely rare in degenerative 
parkinsonism. We propose that the very concept of SWEDD is more confusing than helpful and should be 
deﬁnitely abandoned.
1. Introduction
123I-ioﬂupane (DaTSCAN®) SPECT is one of the most commonly
used molecular imaging methods to assess the integrity of the
nigrostriatal dopamine system [1]. It has proven highly valuable to
conﬁrm degenerative parkinsonisms such as Parkinson’s disease
(PD), multiple system atrophy (MSA), progressive supranuclear
palsy (PSP) and corticobasal degeneration (CBD) [1,2,4].
In most studies, interpretation of 123I-ioﬂupane images has been
based on visual assessment using a 0 (normal) to 3 scaling system
[2,3], the deﬁnition of each abnormal pattern being quite strictly
deﬁned. However, whereas this method has proved quite reliable
[4,5], its ordinal and relatively crude nature has left some room for
intermediate or difﬁcult-to-classify cases, in particular those with
questionable uptake deﬁcit early in the disease course. More
recently, semi-quantitative methods of assessment have been
developed based on the ratio of manually drawn or automatically
delineated striatal regions or volumes of interest (ROIs, VOIs) to
background activity [6,7] using various protocols and software.
While less prone to subjectivity bias or to intra- and inter-observer
variability, these analyses require robust reference values, usually
established on healthy subjects, to which data from individual
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which should be cited to refer to this work.
patients can be compared. However, generalizable reference values
for semi-quantitative analyses are notoriously difﬁcult to deter-
mine due to highly variable acquisition and reconstruction
methods of SPECT imaging.
About a decade ago, several large drug trials on PD progression
and neuroprotection reported that a signiﬁcant proportion (be-
tween 1 and 15%) of patients clinically diagnosed with PD showed a
normal 123I-ioﬂupane SPECT uptake [8e11]. This unexpected
ﬁnding was found consistent enough across studies to coin the
acronym SWEDD for scan without evidence of dopaminergic
deﬁcit. Various hypotheses were proposed to explain the SWEDD
phenomenon, including that SWEDD patients did not have PD or,
alternatively and in complete contradiction with universally
accepted neuropathological data, that very early PD may be asso-
ciated with an unaltered nigrostriatal pathway or with highly
effective compensatory mechanisms to counteract striatal dopa-
mine decline. Over time, in the absence of clear explanations for it,
the SWEDD concept has become popular and derived into a loose
yet well accepted clinical entity, possibly a new neurological con-
dition variably associating atypical tremor, dystonia, parkinsonism,
gait disturbances, and various non-motor symptoms such as
hyposmia. It soon became clear, however, that the SWEDD popu-
lation was not uniform and included a heterogeneous group of
patients, the vast majority of which did not fulﬁll PD clinical criteria
but have conditions somehow resembling PD, such as essential
tremor, dystonia, drug-induced or psychogenic parkinsonisms,
vascular parkinsonism, fragile X-related tremor ataxia syndrome
(FXTAS) or even aging-related extrapyramidal features. On the
other hand, it appeared that a handful of SWEDD cases reported in
the literature seem to have true PD. In those cases, the diagnosis of
PD was eventually retained based on follow-up observations of
disease progression, levodopa responsiveness or a repeated scan
that was found abnormal [12e14]. Therefore, a normal scan in cases
suspected to have a degenerative presynaptic parkinsonism, i.e.
affecting the nigrostriatal system, may be seen in three distinct
situations that could occur either alone or in combination: (1)
clinical diagnosis is erroneous (i.e. patient has a non-degenerative
condition); (2) scan interpretation is incorrect; and (3) indeed,
degenerative presynaptic parkinsonism, notably PD, might be
associated with a SWEDD pattern, at least early in the disease
course, mechanisms of which remain to be established.
2. Methods
2.1. Patients
The present study has been conducted in compliance with the
declaration of Helsinki. The protocol has been approved by our local
ethics committee (CER 12-006R). As a retrospective observational
study, no written consent was required. We collected data from
1005 123I-ioﬂupane SPECT scans performed on 970 consecutive
patients at our institution from October 2003 to September 2013.
The vast majority of patients have been evaluated at least once by
trained movement disorders specialists and the following data has
been obtained: gender, age at disease onset, disease duration at the
time of SPECT, body side predominance and ﬁnal clinical diagnosis.
Regarding degenerative parkinsonian syndromes, we used the UK
Parkinson’s Disease Study Brain Bank criteria for PD [15], the sec-
ond consensus statement for the diagnosis of MSA [16], the Na-
tional Institute of Neurological Disorders Society (NINDS) clinical
research criteria for PSP [17] and the criteria for the diagnosis of
CBD proposed by Armstrong et al. [18]. Patients were classiﬁed as
having a non-degenerative parkinsonian syndrome or tremor,
whenever they fulﬁlled the criteria for essential tremor [19], dys-
tonic tremor [20], psychogenic parkinsonism [21] or drug-induced
parkinsonism as described in Ref. [22]. Importantly, most patients
were followed over several years and, in few instances, the diag-
nosis was changed according to the appearance of new features
supporting another parkinsonian syndrome. In these cases, it is the
last, more likely diagnosis which was retained. Finally, 33 patients
had a second or even a third 123I-ioﬂupane SPECT scan and only the
ﬁrst one was considered for the collecting step of our study. Please
refer to Fig. 1 for details of study enrollment.
2.2. Imaging: acquisition and reconstruction
123I-FP-CIT SPECT was performed according to the manufac-
turer’s instructions. Patients received 185 MBq of ioﬂupane in slow
intravenous injection and were administered Lugol solution or
sodium perchlorate for thyroid blockade. SPECT data acquisition
started 4 h after ioﬂupane administration.
All scans were acquired on the same triple-head gamma camera
(GCA-9300A/UI Toshiba Medical Systems AG, Oetwil am See,
Switzerland) equipped with fan beam, low-energy, high-resolution
collimators. Details of the acquisition and reconstruction are
available elsewhere [22].
2.3. Imaging: data analysis
123I-ioﬂupane SPECT images were classiﬁed according to the
standard 0-to-3 visual staging system [2,3], as available in the nu-
clear medicine report written at the time of scan.
2.4. Determination of local semi-quantitative reference values
Establishment of local reference values has been reported pre-
viously using a large cohort of patients with non-degenerative
conditions and a normal 123I-ioﬂupane SPECT scan [22]. Impor-
tantly, it has been demonstrated that data obtained from this
population were nearly identical with those from healthy subjects,
thus validating the method. Regarding striatum, putamen (P) and
caudate nucleus (C) uptake values, cut-off points were taken at the
5th percentile of the cohort of subjects with non-degenerative
conditions. Uptake was considered as abnormal when below
3.93074e0.02156  age for striatum, 3.79744e0.02168  age for P
and 4.03099e0.02141  age for C. For example, a 70-year-old pa-
tient is expected to have uptake values above 2.42 for striatum, 2.28
for P and 2.53 for C. For striatal asymmetry index (AI) and C/P ratio,
cut-off was established at the 95th percentile. Thus, a value above
12.22 was considered abnormal regarding striatal AI, whereas C/P
ratio >1.30 indicated a pathological scan.
2.5. Identiﬁcation of SWEDD cases and scans reassessment
We ﬁrst collected all patients with a clinical diagnosis of
degenerative parkinsonism and an initial SPECT scan considered
normal and corresponding to a visual grade of 0 on the initial report
(when the scan was performed). We then established automated
BRASS™ semi-quantitative values for right and left C, P and stria-
tum, as well as striatal AI and C/P ratio and compared them to our
local semi-quantitative age-dependent reference values. In parallel,
two experts (one movement disorders specialist (PB) and one nu-
clear medicine specialist (VG), both well trained in 123I-ioﬂupane
SPECT interpretation) reviewed in detail the visual staging of all
scans in all planes using 3D images. Experts were blinded to the
clinical diagnosis, as these grade-0 scans were reviewed among a
collection of normal scans from patients with non-degenerative
conditions independently prepared by another researcher (NN).
At the end of this double cross-control assessment, we calculated
the proportion of patients whose both visual staging review and
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semi-quantitative SPECT values were normal, representing deﬁnite
SWEDD patients in our cohort. In addition, we applied our on-site
reference values to the whole cohort to compare the results of
the semi-quantitative method with the initial visual assessment.
Finally, we assessed the evolution of images in those patients in
whom more than one scan was performed.
3. Results
As shown in Fig. 1, 422 patients diagnosed with a degenerative
parkinsonian syndrome were identiﬁed. Twelve subjects were
excluded because tridimensional SPECT images were not available
for re-analysis, so that BRASS™-derived semi-quantitative values
could not be obtained. A total of 410 patients were eventually
included in this study. Clinical diagnoses were PD (n ¼ 322), MSA
(n ¼ 22), PSP (n ¼ 33) and CBD (n ¼ 33). Mean age was 69.4 ± 11.1
years (range 25e92), with a 51.6% male proportion, mean disease
duration at the time of scan was 4.2 ± 4.7 years for PD, 2.9 ± 2.2 for
MSA, 1.8 ± 0.9 for PSP and 2.5 ± 1.5 years for CBD patients. For PD
patients, mean Hoehn & Yahr (H&Y) stage was estimated as
2.4 ± 0.9. Importantly, 136 subjects (33%) from the whole cohort
had a disease duration less than one year when scan was per-
formed, including 103 (32%) from the 322 PD patients, and 33 (37%)
from the 88 non-PD patients.
3.1. Initial visual staging
Ten patients (2.4%) had an initial visual staging considered as
normal (stage 0). Characteristics of these 10 patients, correspond-
ing to typical SWEDD cases according to the literature, are sum-
marized in Table 1. Of note, a second 123I-ioﬂupane SPECT scan has
been performed in 7 of these patients and for all 7, the repeated
scan was clearly abnormal (stage 1 or 2).
Clinical diagnosis of patients with stage 0 SPECT was PD (50%, 5/
10), MSA (10%, 1/10), PSP (20%, 2/10) and CBD (20%, 2/10), corre-
sponding to a proportion to the whole diagnostic group of 1.6% for
PD (5/322), 4.5% for MSA (1/22), 6.1% for PSP and for CBD (2/33 for
each). Disease duration at the time of scan by diagnostic category
was of 1.6 ± 1.6 years for PD (after excluding a single patient with a
10-year evolution as an outlier), 0.5 year for the patient with MSA,
0.8 ± 0.4 for PSP and 1.5 ± 0.7 years for CBD. PD patients’ mean H&Y
stagewas 2.4 ± 1.5 (range 1e5) at the time of scan. Disease duration
at the time of scan for PD patients with normal initial visual
assessment was signiﬁcantly lower than that of the whole cohort of
PD patients (1.6 ± 1.6 years vs 4.2 ± 4.7, p < 0.003, Student t-test).
Regarding the cohort of provisional SWEDD, disease duration
(2.2 ± 3.0 years) was lower than that of the whole cohort of
degenerative parkinsonism (3.8 ± 4.4, p ¼ 0.12).
3.2. Semi-quantitative BRASS™ analysis of SPECT with normal
visual analysis
Semi-quantitative evaluation of those 10 patients exhibiting a
normal visual assessment showed that only 2 patients (20%) had a
strictly normal semi-quantitative assessment. For the 7 patients
who had a second 123I-ioﬂupane SPECT scan, semi-quantitative
analysis of the ﬁrst scan already showed abnormal values for
each of these cases (7/7, 100%). The two patients with initial normal
visual assessment and unaltered semi-quantitative values carried a
clinical diagnosis of CBD.
3.3. Application of BRASS™-derived striatal uptake reference values
for the whole cohort
When applying our on-site reference values for C, P and stria-
tum, including AI and C/P ratio, on the whole cohort of patients
with degenerative parkinsonism and available SPECT images
(n ¼ 410), only 10/410 (2.4%) were considered to have a normal
independent semi-quantitative assessment. Clinical characteristics,
as well as initial and reassessed visual staging are summarized in
Table 2. Regarding this group, disease duration was lower than that
of the whole cohort (2.1 ± 2.1 years vs 3.8 ± 4.4, p ¼ 0.11). Among
these 10 patients, two had a concomitant stage 0 initial visual
assessment, while eight patients had an abnormal (stage 1e2) vi-
sual staging.
Fig. 1. Diagram showing the general categorization of patients who had a 123I-ioﬂupane SPECT in Geneva from 2003 to 2013. DIP: drug-induced parkinsonism - ET: essential tremor
- PP: psychogenic parkinsonism e DT: dystonic tremor - PD: Parkinson’s disease e MSA: multiple-system atrophy e PSP: progressive supranuclear palsy e CBD: corticobasal
degeneration e DLB: dementia with Lewy bodies e AD: Alzheimer’s disease e FTLD: frontotemporal lobe dementia e VD: vascular dementia e VP: vascular parkinsonism e NPH:
normal-pressure hydrocephalus.
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3.4. Review of visual staging
In parallel, two experts in 123I-ioﬂupane SPECT analysis reas-
sessed the visual stage of the 10 patients with a potential SWEDD
status, based on the initial visual stage. Only 1/10 (10%) exhibited a
deﬁnitely normal (stage 0) visual assessment. This patient was
among the two with normal semi-quantitative values. Potential
causes of stage misattribution that were identiﬁed by the experts
included: misalignment of scan images, heterogeneity of uptake
patterns and underestimation of P size.
3.5. Deﬁnite SWEDD patients
Taking together both evaluations methods (semi-quantitative
analysis and expert review of scans), only one patient (1/410, 0.24%)
with a degenerative form of parkinsonism had a strictly normal
123I-ioﬂupane SPECT. At the time of scan, this 56-year-old male
patient exhibited a rapidly progressive, highly asymmetrical non-
tremulous akinetic-rigid syndrome associated with parietal lobe-
type sensory symptoms including ideo-motor apraxia and alien
limb phenomenon, which were all unresponsive to high doses of
levodopa and dopamine agonists, thus fulﬁlling a diagnosis of
probable CBD. Axial images of his SPECT scan are shown in Fig. 2. Of
note, none of the 322 PD patients could be labeled as SWEDD, even
those 103 cases where scans were performed very early, less than a
year after disease onset.
4. Discussion
From one of the largest 123I-ioﬂupane SPECT-assessed cohort of
degenerative parkinsonism patients studied yet, we identiﬁed 10
cases (2.4% of 410 patients) in whom routine visual interpretation
yielded a normal scan result, corresponding to typical SWEDD cases
as reported in the literature. An extensive, two-step reassessment
of these scans, using the automated semi-quantitative BRASS™
software and locally established reference values as well as
diagnosis-blinded detailed expert reviews, showed that all but one
SWEDD cases (0.24% of 410 patients) with CBD actually had a
deﬁnitely abnormal 123I-ioﬂupane SPECT and not a single patient
with PD could be considered a true SWEDD, casting serious doubts
about published estimates of the real prevalence of SWEDD in
degenerative parkinsonism and, in general, about the very useful-
ness of the SWEDD concept.
Mean age of the 10 patients with a provisional SWEDD label was
similar to that of our global cohort of degenerative parkinsonisms,
yet they had a trend toward a shorter disease duration at the time
of scan (2.2 ± 3.0 vs 3.8 ± 4.4 years, p ¼ 0.12).
Scans from this population of 10 provisional SWEDD cases were
then extensively reassessed. First, applying semi-quantitative
assessment yielded only two subjects with normal values. This
supports our early hypothesis that routine visual assessment alone
may not be reliable enough to deﬁne scan normality, at least in
some cases with borderline uptakes, as already shown in a previous
study [22]. Second, a detailed review of the visual stage by two
experts showed that only one of these 10 patients could be
considered as having a deﬁnite normal (stage 0) visual assessment.
This further comforts the notion that visual inspection is prone to
inter-observer variability and that the level of expertise in assessing
scans may be crucial in the ﬁnal staging attribution. Third, in seven
cases, a second 123I-ioﬂupane SPECT scan was repeated a few years
later because of disease progression that was felt inconsistent with
the initial scan graded as normal. For all these seven patients, not
Table 1
Characteristics of patients with clinical degenerative parkinsonism and normal initial visual SPECT assessment, as well as their ﬁndings regarding semi-quantitative
assessment and visual reassessment. A second 123I-ioﬂupane SPECT has been performed for patients whose number is followed by*.
Patient
number
Gender Age (years) Disease Disease duration at the time
of scan (years)
Hoehn & Yahr
scale
Visual
reassessment
(stage)
Semi-quantitative
evaluation
1* M 78 PD 1 2 1 Abnormal
2* M 44 Young-onset PD (PARK2) 10 2 1 Abnormal
3* M 33 Young-onset PD 1 1 1 Abnormal
4* F 68 PD 4 2 1 Abnormal
5* F 68 PD and DIP 0.5 5 1 Abnormal
6* M 65 MSA-P 0.5 1 Abnormal
7* M 70 PSP 0.5 1 Abnormal
8 M 69 PSP 1 1 Abnormal
9 F 69 CBD 1 1 Normal
10 M 56 CBD 2 0 Normal
Mean 62.0 ± 13.7
(range 33e78)
5/322 PD (1.6%), 1/22 MSA (4.5%), 2/33 PSP
(6.1%), 2/33 CBD (6.1%)
Mean 2.2 ± 3.0 (range 0.5
e10)
Mean 2.4 ± 1.5
(range 1e5)
Table 2
Characteristics of patients with clinical degenerative parkinsonism and normal semi-quantitative assessment. In addition, initial visual assessment, as well as visual review is
mentioned.
Number Gender Age Disease Disease duration (years) Initial visual stage Visual review
1 F 88 PD 1 1
2 F 79 PD 3 3
3 F 65 PD 1 1
4 F 89 PD 0.5 2
5 F 79 PD 1 2
6 F 68 PD 0.5 1
7 M 77 PD 7 1
8 F 69 CBD 1 0 1
9 F 76 CBD 4 2
10 M 56 CBD 2 0 0
M/F ratio 2/8 ¼ 0.25 7/10 PD 3/10 CBD 2.5 ± 2.2 (range 1e7) 1.3 ± 0.9 (range 0e3)
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only was the second scan considered as deﬁnitely abnormal (stage
1 or 2), thus conﬁrming the clinical suspicion of a degenerative
condition, but, interestingly, uptake values of some VOIs of the ﬁrst
scan were also below reference limits. In these cases, a correct
interpretation of the ﬁrst scan would likely have spared the second
one. Sensitivity of initial visual and semi-quantitative analyses is
similar when considered independently. However, assessments
taken in combination allow a greater sensitivity for determination
of nigro-striatal impairment.
In previous studies, an incorrect initial diagnosis of degenerative
parkinsonism seems to account for a signiﬁcant proportion of
SWEDDs [12,13,23] and, in those studies where a second, follow-up
scan has been performed, conversion from normal to abnormal was
rather uncommon (8.3% in Ref. [13] and 12.5% in Ref. [24]).
Conversely, at the 22-month follow-up time point of the PRECEPT
study [13], 3 out of 629 cases with an initial abnormal scan (0.5%)
switched to a normal category, implying that the ﬁrst scan was
incorrectly assigned an abnormal label. However, in none of the
studies mentioned above was the quality of the scan interpretation
challenged or even discussed, yet the need for semi-quantitative
values has been strongly suggested in recent publications [4,6],
further supported by the ﬁnding of a direct correlation between
dopamine transporter uptake and neuromelanin-positive nigral
cell count on pathological specimens [25]. Technical issues
(misalignment of scan, medication interfering with dopaminergic
uptake of SPECT) can also play a role. With respect to the diagnostic
issue, it is important to underline that virtually all patients included
in our study were followed over time, usually for many years, and
this allowed disease progression, the main criterion supporting a
degenerative process at the basis of the observed clinical features,
to be captured. In addition, the vast majority of patients were
managed by movement disorders specialists and clinical diagnoses
were established according to the more recent, validated and
widely used criteria. For example, in the case of PD, the presence of
a tremor alone, even at rest, did not qualify for a diagnosis of PD and
such patients were not even enrolled in this study.
In this series, SWEDDweremore common in CBD patients (6.1%)
compared to the other forms of degenerative parkinsonism. This
may not be unexpected as it is well known that CBD neuro-
degeneration tends to start in cortical areas whereas basal ganglia
are implicated later in the disease [26], possibly accounting for
higher DAT uptake early in the disease course. This is not totally
surprising nor is it new, as at least two cases of pathology-proven
CBD with normal dopaminergic SPECT have been published so far
[27,28].
In conclusion, our study strongly suggests that a high proportion
of SWEDD cases may be related to an incorrect visual interpretation
of 123I-ioﬂupane SPECT scans, rather than or in addition to an
erroneous clinical diagnosis. Interestingly, we were unable to
identify a single case of PD associated with a normal scan thanks to
our combined reassessment, even very early in the disease course,
fully supporting the recently proposed MDS clinical criteria for PD,
where a normal scan is considered an absolute exclusion criterion
[29]. Based on our results and the confusing literature surrounding
it, we concur with other researchers [30] that the very concept of
SWEDD is clinically and scientiﬁcally highly problematic and
should be deﬁnitely abandoned.
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